--- title: "Pyxis Oncology (PYXS) news: going concern and offering" url: "https://aibio.space/companies/pyxis-oncology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PYXS going concern and offering news: Pyxis Oncology prices $109,998,133 stock and warrant offering at $2.90. Pyxis Oncology, Inc." --- PYXS Pyxis Oncology, Inc. NASDAQ · United States # Pyxis Oncology (PYXS) news PYXS going concern and offering news Financings · 2026-09-29 ## [Pyxis Oncology prices $109,998,133 stock and warrant offering at $2.90](https://aibio.space/news/pyxis-oncology-prices-109-998-133-stock-warrant-offering-2-90/) Pyxis Oncology is selling 36,047,919 shares at $2.900 and pre-funded warrants, with common warrants at $3.50 that cannot be exercised until stockholders approve more authorized shares. Its auditor's report on the 2025 financial statements carries a going-concern warning. ## Latest Pyxis Oncology news 1. 2026-07-02 Financings [Pyxis Oncology agrees to sell about $50 million of stock and warrants in private placement](https://aibio.space/news/pyxis-oncology-agrees-sell-about-50-million-stock-warrants-private/) Pyxis Oncology agreed to sell 19,600,153 shares at $2.551 and warrants at $3.289 to investors led by BVF Partners L.P. The press release says the upfront money extends cash into the second quarter of 2027, while the company's annual report carried a going-concern warning and said cash would fund operations only into the fourth quarter of 2026. ## Pyxis Oncology at a glance - **Ticker**: PYXS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $33.0 million ### Related companies - [Vicapsys Life Sciences](https://aibio.space/companies/vicapsys-life-sciences/) OTC: VICP - [Eledon Pharmaceuticals](https://aibio.space/companies/eledon-pharmaceuticals/) NASDAQ: ELDN - [Seaport Therapeutics](https://aibio.space/companies/seaport-therapeutics/) NASDAQ: SPTX - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) NASDAQ: PCSA - [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) NASDAQ: PBYI - [Ocean Biomediacal](https://aibio.space/companies/ocean-biomediacal/) OTC: OCEA - [Northwest Biotherapeutics](https://aibio.space/companies/northwest-biotherapeutics/) OTC: NWBO - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) NASDAQ: BFRI ### Also on NASDAQ - [Oculis Holding](https://aibio.space/companies/oculis/) OCS - [Orchestra BioMed Holdings](https://aibio.space/companies/orchestra-biomed/) OBIO - [Polyrizon](https://aibio.space/companies/polyrizon/) PLRZ - [IMMUCELL CORP /DE/](https://aibio.space/companies/immucell-de/) ICCC - [BioMarin Pharmaceutical](https://aibio.space/companies/biomarin-pharmaceutical/) BMRN - [SERA PROGNOSTICS, INC.](https://aibio.space/companies/sera-prognostics/) SERA ## What Pyxis Oncology does Pyxis Oncology is a clinical-stage oncology company developing treatments for solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Its lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B of fibronectin (EDB+FN), a component of the tumor microenvironment. The company describes a three-part mechanism in which the released payload kills cancer cells directly, spreads to nearby cancer cells through a bystander effect, and triggers immunogenic cell death. MICVO is being studied as a monotherapy in recurrent and metastatic HNSCC and in combination with KEYTRUDA (pembrolizumab) in first-line and later-line recurrent and metastatic HNSCC and other solid tumors. A Phase 1 monotherapy dose expansion began in January 2025 at 5.4 mg/kg. The combination study, PYX-201-102, is a Phase 1/2 trial that is actively enrolling. Merck & Co., Inc. (Merck) provides KEYTRUDA under a Clinical Trial Collaboration and Supply Agreement with the company. | Product or program | What it is | Stage | |---|---|---| | Micvotabart pelidotin (MICVO, formerly PYX-201) | Antibody-drug conjugate targeting extradomain-B of fibronectin in solid tumors | Phase 1 monotherapy dose expansion (Part 2) in R/M HNSCC | | MICVO with KEYTRUDA (PYX-201-102) | Combination study of MICVO with pembrolizumab in advanced solid tumors | Phase 1/2, actively enrolling | Summarised from the company's [10-K filed Mar 23, 2026](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/pyxs-20251231.htm). ## Pyxis Oncology annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$13.9 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | [$16.1 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | | Research and development | [$73.7 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | [$58.7 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | | Net income (loss) | [-$79.6 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | [-$77.3 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | | Cash from operations | [-$63.5 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | [-$57.7 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | | Cash and equivalents | [$15.4 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526347913/) | [$19.5 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | | Short-term investments | [$51.4 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526347913/) | [$107.5 million](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $18.9 million, plus short-term investments of $14.1 million, $33.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Pyxis Oncology Has Pyxis Oncology issued a going-concern warning? Our latest story on this, dated Sep 29, 2026: "Pyxis Oncology prices $109,998,133 stock and warrant offering at $2.90". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pyxis-oncology-prices-109-998-133-stock-warrant-offering-2-90/). Has Pyxis Oncology raised money recently? Our latest story on this, dated Sep 29, 2026: "Pyxis Oncology prices $109,998,133 stock and warrant offering at $2.90". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pyxis-oncology-prices-109-998-133-stock-warrant-offering-2-90/). What is the ticker symbol of Pyxis Oncology? Pyxis Oncology, Inc. trades under the ticker PYXS on NASDAQ. Where is Pyxis Oncology listed? Pyxis Oncology, Inc. is listed on NASDAQ. What is the SEC CIK of Pyxis Oncology? The SEC Central Index Key (CIK) for Pyxis Oncology, Inc. is 1782223. Its filings are on SEC EDGAR. How many shares does Pyxis Oncology have outstanding? 83,408,050 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Pyxis Oncology listed under? Our directory records Pyxis Oncology, Inc. under United States. What does Pyxis Oncology do? Our directory classifies Pyxis Oncology, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Pyxis Oncology? The ISIN recorded for Pyxis Oncology, Inc. is US7473241013. Does aibio.space cover Pyxis Oncology? aibio.space lists Pyxis Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Pyxis Oncology incorporated? SEC records list its state or country of incorporation as DE. What does Pyxis Oncology develop? Pyxis Oncology is a clinical-stage oncology company developing treatments for solid tumors, with an immediate focus on head and neck squamous cell carcinoma (HNSCC). Its lead product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B of fibronectin (EDB+FN), a component of the tumor microenvironment. What is Micvotabart pelidotin (MICVO, formerly PYX-201) from Pyxis Oncology? Micvotabart pelidotin (MICVO, formerly PYX-201): Antibody-drug conjugate targeting extradomain-B of fibronectin in solid tumors Stage: Phase 1 monotherapy dose expansion (Part 2) in R/M HNSCC. What is MICVO with KEYTRUDA (PYX-201-102) from Pyxis Oncology? MICVO with KEYTRUDA (PYX-201-102): Combination study of MICVO with pembrolizumab in advanced solid tumors Stage: Phase 1/2, actively enrolling. What was Pyxis Oncology's revenue last year? $13.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Pyxis Oncology Members talk about Pyxis Oncology (PYXS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Pyxis Oncology, newest first. Each line links the filing it comes from. 1. 2026-09-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1782223/000143774926031470/pyxs20260909c_424b5.htm) 2. 2026-08-20 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1782223/000119312526359246/pyxs-20260820.htm) 3. 2026-07-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1782223/000119312526294613/pyxs-ex99_1.htm) 4. 2025-11-26 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1782223/000143774925036389/pyxs20251125_s3.htm) 5. 2025-11-03 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1782223/000119312525261696/pyxs-20250930.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PYXS on TradingView](https://www.tradingview.com/symbols/NASDAQ-PYXS/). ## SEC filings and registration - **SEC name**: Pyxis Oncology, Inc. - **CIK**: 1782223 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PYXS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 321 HARRISON AVENUE, BOSTON, MA, 02118 - **Phone**: (617) 221-9059 - **Shares outstanding**: 83,408,050 as of 2026-08-12 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1782223/000119312526427882/def_14a_oct_26.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1782223/000143774926031767/pyxs20261001_8k.htm) filed 2026-10-01 - [424B5](https://www.sec.gov/Archives/edgar/data/1782223/000143774926031667/pyxs20260930_424b5.htm) filed 2026-10-01 - [424B5](https://www.sec.gov/Archives/edgar/data/1782223/000143774926031480/pyxs20260909_424b5.htm) filed 2026-09-29 - [424B5](https://www.sec.gov/Archives/edgar/data/1782223/000143774926031470/pyxs20260909c_424b5.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1782223/000119312526385901/pyxs-20260909.htm) filed 2026-09-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/pyxs-20260903.htm) filed 2026-09-08 - [S-3](https://www.sec.gov/Archives/edgar/data/1782223/000119312526359246/pyxs-20260820.htm) filed 2026-08-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001782223), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Pyxis Oncology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PYXS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Pyxis Oncology, Inc. - **Ticker**: PYXS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US7473241013 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PYXS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pyxis-oncology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Pyxis Oncology (PYXS) news: going concern and offering", 2026-10-31, https://aibio.space/companies/pyxis-oncology/